Literature DB >> 9325248

Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL.

M MacFarlane1, M Ahmad, S M Srinivasula, T Fernandes-Alnemri, G M Cohen, E S Alnemri.   

Abstract

A human receptor for the cytotoxic ligand TRAIL (TRAIL receptor-1, designated DR4) was identified recently as a member of the tumor necrosis factor receptor family. In this report we describe the identification of two additional human TRAIL receptors, TRAIL receptor-2 and TRAIL receptor-3, that belong to the tumor necrosis factor receptor family. Interestingly, TRAIL receptor-2 but not TRAIL receptor-3 contains a cytoplasmic "death domain" necessary for induction of apoptosis and is hence designated death receptor-5 (DR5). Like DR4, DR5 engages the apoptotic pathway independent of the adaptor molecule FADD/MORT1. Because of its lack of a death domain, TRAIL receptor-3 is not capable of inducing apoptosis. However, by competing for TRAIL, it is capable of inhibiting TRAIL-induced apoptosis. Thus, TRAIL receptor-3 may function as an antagonistic decoy receptor to attenuate the cytotoxic effect of TRAIL in most tissues that are TRAIL+, DR4+, and DR5+.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9325248     DOI: 10.1074/jbc.272.41.25417

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  124 in total

Review 1.  Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.

Authors:  B G Darnay; B B Aggarwal
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Elevated extracellular [K+] inhibits death-receptor- and chemical-mediated apoptosis prior to caspase activation and cytochrome c release.

Authors:  G J Thompson; C Langlais; K Cain; E C Conley; G M Cohen
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

3.  A fifteen-amino-acid TVB peptide serves as a minimal soluble receptor for subgroup B avian leukosis and sarcoma viruses.

Authors:  Daniel J Knauss; John A T Young
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

4.  B lymphocytes are resistant to death receptor 5-induced apoptosis.

Authors:  Roslyn N Crowder; Hong Zhao; W Winn Chatham; Tong Zhou; Robert H Carter
Journal:  Clin Immunol       Date:  2011-01-28       Impact factor: 3.969

5.  Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling.

Authors:  Maike A Laussmann; Egle Passante; Christian T Hellwig; Bartlomiej Tomiczek; Lorna Flanagan; Jochen H M Prehn; Heinrich J Huber; Markus Rehm
Journal:  J Biol Chem       Date:  2012-03-09       Impact factor: 5.157

Review 6.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 7.  Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?

Authors:  Guillaume Jacquemin; Sarah Shirley; Olivier Micheau
Journal:  Cell Mol Life Sci       Date:  2010-05-29       Impact factor: 9.261

8.  Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5.

Authors:  Tai-Guang Jin; Alexei Kurakin; Nordine Benhaga; Karon Abe; Mehrdad Mohseni; Ferry Sandra; Keli Song; Brian K Kay; Roya Khosravi-Far
Journal:  J Biol Chem       Date:  2004-10-14       Impact factor: 5.157

9.  Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

Authors:  Teresa Troiani; Erika Martinelli; Floriana Morgillo; Anna Capasso; Anna Nappi; Vincenzo Sforza; Fortunato Ciardiello
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

10.  Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.

Authors:  Leo Christopher DeRosier; Donald J Buchsbaum; Patsy G Oliver; Zhi-Qiang Huang; Jeffrey C Sellers; William E Grizzle; Wenquan Wang; Tong Zhou; Kurt R Zinn; Joshua W Long; Selwyn M Vickers
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.